1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork

1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork

User Photo
obr

7 months
12 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma.
Up Next Autoplay